ArticleJournal for immunotherapy of cancer2025

A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer.

Jingqi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.